ArticleAnalytical and bioanalytical chemistry2025
UPLC-Q-TOF-MS/MS and NMR studies for the structural characterization of degradation impurities of rimegepant.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rimegepant is a type of medication classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, used to treat migraines. The present research focused to identify and characterize its degradation products using the liquid chromatography-high-resolution mass spectrometry (Q-TOF-HRMS) and nuclear magnetic resonance spectroscopy (NMR). The degradation profile of rimegepant was evaluated using forced degradation studies, which included exposure to hydrolysis, oxidation, photolysis, and thermal conditions. The drug degraded under hydrolytic and oxidative conditions whereas it was found to be stable under photolytic and thermal conditions. An Acquity CSH C18 column (2.1 × 100 mm; 1.7 µm) was used to separate the analytes using a mobile phase of 0.1% formic acid in water and 0.1% formic acid in acetonitrile eluting in gradient mode at a flow rate of 0.3 mL/min. The degradation products were separated and identified using the mass fragmentation and accurate mass information obtained from LC-MS. A preparative HPLC was used to isolate the major degradation products for structural identification through 1D and 2D NMR studies. According to ICH Q2 (R1) guidelines, the developed UHPLC-PDA method was validated for its accuracy, precision, linearity, and specificity.
Indexed as
Identifiers
40085213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.